Leap Therapeutics Inc (fra:5MC) Share Price

Company Profile

Business description
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Contact
47 Thorndike Street
Suite B1-1
CambridgeMA02141
USA
T: +1 617 714-0360
E: [email protected]
https://www.leaptx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
54

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,062.21	33.93	0.42%
DAX 40	23,118.15	131.33	0.57%
Dow JONES (US)	41,621.36	133.17	0.32%
FTSE 100	8,675.95	43.62	0.51%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,777.37	23.29	0.13%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,166.14	100.11	-0.82%
S&P 500	5,660.34	21.40	0.38%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%